Lupin launches generic Fenofibric Acid capsules in US market

Lupin said its US arm has launched generic Fenofibric Acid capsules used for reducing cholesterol and fatty acids in the blood in the American market.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news

Related Links:

Contributors : Masashi Muramatsu ; Suguru Nakagawa ; Tsuyoshi Osawa ; Takashi MinamiSeries Type : Expression profiling by arrayOrganism : Mus musculusTo elucidate the molecular mechanisms behind corneal angiogenesis in Dscr-1-/- mice, we performed microarray analysis using intact corneas from B6, Dscr-1-/- mice, ApoE-/- mice, Dscr-1-/- and ApoE-/- double null mutant mice and sutured corneas from B6, Dscr-1-/- and Dscr-1 Tg mouse.
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Mus musculus Source Type: research
Statins are the only Class I ISHLT recommendation in heart transplantation (HT) as an established therapy to reduce cardiac allograft vasculopathy (CAV) and improve survival. However, the goal LDL is not known with no formal recommendation on targets. We assessed if LDL
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: (553) Source Type: research
Primary graft dysfunction (PGD) is the main cause of mortality during the first month and the second one within the first year after lung transplant (LT) Statins, 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors, have shown to have immunomodulatory and antiinflamatory effects unrelated to their cholesterol-lowering function. We hypothesized that recipient's preoperative statin therapy is associated with decreased incidence of PGD after LT.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: (383) Source Type: research
This study aims to examine the efficacy of high-intensity statin therapy compared to low-intensity, moderate-intensity, or no statins at preventing cardiac allograft vasculopathy (CAV) and related outcomes of rejection and mortality after cardiac transplant in the setting of tacrolimus as primary calcineurin inhibitor.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: (508) Source Type: research
In this study, we analyzed myocardial gene expression profiles in cardiac allografts after donor simvastatin treatment.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: (192) Source Type: research
Left ventricular (LV) global longitudinal strain (GLS) is a robust marker of subclinical myocardial dysfunction. Previous studies showed that as small as 2% reduction in GLS predicted major adverse event in heart transplant (HT) recipients, including cardiac allograft vasculopathy (CAV). Although low intensity statin is commonly used after HT to reduce CAV, the incremental impact of statin intensity on myocardial function is unknown.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: (616) Source Type: research
ConclusionsStatin initiators had a lower risk of any ALI outcome compared with non-users within 18  months regardless of HIV and/or HCV status.
Source: American Journal of Cardiovascular Drugs - Category: Cardiology Source Type: research
PCSK9 inhibitor alirocumab lowered LDL cholesterol by 35% over placebo in ODYSSEY HoFH, the largest ever randomized lipid-lowering trial in homozygous familial hypercholesterolemia.Medscape Medical News
Source: Medscape FamilyMedicine Headlines - Category: Primary Care Tags: Cardiology News Source Type: news
ABSTRACTSerum lipid abnormalities (dyslipidemias) are major risk factors for cardiovascular disease in type 2 diabetes. The features of diabetic dyslipidemia are elevated plasma concentrations of triglyceride (TG) ‐rich lipoproteins (TRLs), small dense low‐density lipoprotein cholesterol (sdLDL‐C) and decreased plasma high‐density lipoprotein cholesterol (HDL‐C) concentration
Source: Journal of Diabetes Investigation - Category: Endocrinology Authors: Tags: JDI UPDATES Source Type: research
As the COVID-19 outbreak worsens in the U.S., at-home test kits for the virus have been a source of both hope and controversy. Their appeal is clear: sick individuals could get a diagnosis from the comfort of home, without infecting others. But their downsides are real: the U.S. Food and Drug Administration (FDA) has cracked down on unauthorized at-home COVID-19 tests, updating its emergency use authorization guidelines to exclude at-home test kits and warning Americans that no such tests have received agency authorization. That means startups previously offering these products—such as Everlywell, Nurx and Carbon Hea...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Source Type: news
More News: Biotechnology | Cholesterol | Pharmaceuticals | Trilipix